BG107055A - Оралнa система с контролирано освобождаване на ципрофлоксацин за еднократно дневно приемане - Google Patents

Оралнa система с контролирано освобождаване на ципрофлоксацин за еднократно дневно приемане Download PDF

Info

Publication number: BG107055A
Authority: BG; Bulgaria
Prior art keywords: formulation; ciprofloxacin; agent; resin; tablet
Prior art date: 2000-03-03

Application number

BG107055A

Other languages

Bulgarian (bg)

English (en)

Inventor

Naresh Talwar

John Staniforth

Ashok Rampal

Gour Muckherji

Badri VISHWANATHAN

Brij Khera

Original Assignee

Ranbaxy Laboratories Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-03

Filing date

2002-09-02

Publication date

2003-06-30

2002-09-02 Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited

2003-06-30 Publication of BG107055A publication Critical patent/BG107055A/bg

Links

MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 164
229960003405 ciprofloxacin Drugs 0.000 title claims abstract description 85
239000000203 mixture Substances 0.000 claims abstract description 118
239000003795 chemical substances by application Substances 0.000 claims abstract description 79
230000008961 swelling Effects 0.000 claims abstract description 33
239000003349 gelling agent Substances 0.000 claims abstract description 32
238000013270 controlled release Methods 0.000 claims abstract description 15
239000007916 tablet composition Substances 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims description 89
229940079593 drug Drugs 0.000 claims description 87
238000009472 formulation Methods 0.000 claims description 77
239000011347 resin Substances 0.000 claims description 66
229920005989 resin Polymers 0.000 claims description 66
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 52
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 50
235000010413 sodium alginate Nutrition 0.000 claims description 50
239000000661 sodium alginate Substances 0.000 claims description 50
229940005550 sodium alginate Drugs 0.000 claims description 50
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 40
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 40
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 40
239000004615 ingredient Substances 0.000 claims description 37
235000017557 sodium bicarbonate Nutrition 0.000 claims description 27
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 26
210000002784 stomach Anatomy 0.000 claims description 20
239000002775 capsule Substances 0.000 claims description 19
ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 claims description 19
210000002966 serum Anatomy 0.000 claims description 19
239000012991 xanthate Substances 0.000 claims description 19
230000036470 plasma concentration Effects 0.000 claims description 17
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 12
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 12
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
230000002401 inhibitory effect Effects 0.000 claims description 10
238000013268 sustained release Methods 0.000 claims description 10
239000012730 sustained-release form Substances 0.000 claims description 10
150000001720 carbohydrates Chemical class 0.000 claims description 9
235000016709 nutrition Nutrition 0.000 claims description 9
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
239000007909 solid dosage form Substances 0.000 claims description 8
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
210000000936 intestine Anatomy 0.000 claims description 5
229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
229920003086 cellulose ether Polymers 0.000 claims description 4
229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
230000002035 prolonged effect Effects 0.000 claims description 3
239000002356 single layer Substances 0.000 claims 2
229920003091 Methocel™ Polymers 0.000 claims 1
229920000297 Rayon Polymers 0.000 claims 1
239000000230 xanthan gum Substances 0.000 claims 1
235000010493 xanthan gum Nutrition 0.000 claims 1
229920001285 xanthan gum Polymers 0.000 claims 1
229940082509 xanthan gum Drugs 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 68
238000004090 dissolution Methods 0.000 description 41
239000000454 talc Substances 0.000 description 37
229910052623 talc Inorganic materials 0.000 description 37
239000007789 gas Substances 0.000 description 36
235000019359 magnesium stearate Nutrition 0.000 description 34
230000001186 cumulative effect Effects 0.000 description 28
239000008194 pharmaceutical composition Substances 0.000 description 21
238000010521 absorption reaction Methods 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
239000004480 active ingredient Substances 0.000 description 17
239000011159 matrix material Substances 0.000 description 17
230000002496 gastric effect Effects 0.000 description 16
239000012530 fluid Substances 0.000 description 15
235000002639 sodium chloride Nutrition 0.000 description 12
210000001035 gastrointestinal tract Anatomy 0.000 description 11
239000000314 lubricant Substances 0.000 description 9
230000000694 effects Effects 0.000 description 8
239000008187 granular material Substances 0.000 description 8
230000000717 retained effect Effects 0.000 description 8
239000002253 acid Substances 0.000 description 7
230000002378 acidificating effect Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
239000000599 controlled substance Substances 0.000 description 7
238000012377 drug delivery Methods 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
229920000168 Microcrystalline cellulose Polymers 0.000 description 6
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
239000000227 bioadhesive Substances 0.000 description 6
235000021152 breakfast Nutrition 0.000 description 6
235000014633 carbohydrates Nutrition 0.000 description 6
239000001768 carboxy methyl cellulose Substances 0.000 description 6
235000015165 citric acid Nutrition 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
235000019813 microcrystalline cellulose Nutrition 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
229920002125 Sokalan® Polymers 0.000 description 5
239000008101 lactose Substances 0.000 description 5
235000012054 meals Nutrition 0.000 description 5
238000002156 mixing Methods 0.000 description 5
230000035764 nutrition Effects 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
239000008279 sol Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
229920003095 Methocel™ K15M Polymers 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
230000036765 blood level Effects 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000012458 free base Substances 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
239000002245 particle Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
210000002438 upper gastrointestinal tract Anatomy 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
229920003094 Methocel™ K4M Polymers 0.000 description 3
230000002745 absorbent Effects 0.000 description 3
239000002250 absorbent Substances 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical group Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 3
229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
235000020937 fasting conditions Nutrition 0.000 description 3
239000000945 filler Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 3
235000017550 sodium carbonate Nutrition 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
229920003119 EUDRAGIT E PO Polymers 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000002720 Malnutrition Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000002585 base Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
229940031304 ciprofloxacin 1000 mg Drugs 0.000 description 2
238000013267 controlled drug release Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
-1 organic acid salt Chemical class 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
239000004584 polyacrylic acid Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229940080313 sodium starch Drugs 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000000112 undernutrition Nutrition 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000208818 Helianthus Species 0.000 description 1
235000003222 Helianthus annuus Nutrition 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000589636 Xanthomonas campestris Species 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
ZQOMKIOQTCAGCM-UHFFFAOYSA-L [Na+].[Na+].OS(O)(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Na+].[Na+].OS(O)(=O)=O.[O-]S([O-])(=O)=O ZQOMKIOQTCAGCM-UHFFFAOYSA-L 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000010564 aerobic fermentation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940085942 formulation r Drugs 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000003292 glue Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
239000011346 highly viscous material Substances 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000000034 method Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
238000007873 sieving Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG107055A 2000-03-03 2002-09-02 Оралнa система с контролирано освобождаване на ципрофлоксацин за еднократно дневно приемане BG107055A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51788700A	2000-03-03	2000-03-03
PCT/IB2001/000279 WO2001064183A1 (en)	2000-03-03	2001-02-28	Orally administered controlled delivery system for once daily administration of ciprofloxacin

Publications (1)

Publication Number	Publication Date
BG107055A true BG107055A (bg)	2003-06-30

Family

ID=24061635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107055A BG107055A (bg)	2000-03-03	2002-09-02	Оралнa система с контролирано освобождаване на ципрофлоксацин за еднократно дневно приемане

Country Status (31)

Country	Link
EP (1)	EP1263409A1 (pl)
JP (1)	JP2003525229A (pl)
KR (1)	KR20030009374A (pl)
CN (1)	CN1420763A (pl)
AP (2)	AP2001002084A0 (pl)
AR (1)	AR032614A1 (pl)
AU (1)	AU3589701A (pl)
BG (1)	BG107055A (pl)
BR (1)	BR0108958A (pl)
CA (1)	CA2400950A1 (pl)
CZ (1)	CZ20022883A3 (pl)
DO (1)	DOP2001000130A (pl)
EA (1)	EA200200914A1 (pl)
EC (1)	ECSP013952A (pl)
EE (1)	EE200200497A (pl)
GT (1)	GT200100033A (pl)
HN (1)	HN2001000038A (pl)
HR (1)	HRP20020715A2 (pl)
HU (1)	HUP0204417A3 (pl)
IL (1)	IL151553A0 (pl)
IS (1)	IS6532A (pl)
MX (1)	MXPA02008568A (pl)
NO (1)	NO20024108L (pl)
NZ (1)	NZ520927A (pl)
OA (1)	OA12381A (pl)
PE (1)	PE20011113A1 (pl)
PL (1)	PL365071A1 (pl)
SK (1)	SK12542002A3 (pl)
WO (1)	WO2001064183A1 (pl)
YU (1)	YU66202A (pl)
ZA (1)	ZA200206764B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
US20030229101A1 (en) *	2002-06-06	2003-12-11	Sherman Bernard Charles	Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (de)	2003-11-04	2005-06-09	Bayer Healthcare Ag	Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ATE396710T1 (de) *	2005-07-19	2008-06-15	Ethypharm Sa	Gastroretentive zusammensetzungen und verfahren zur herstellung
EP1880722B1 (en) *	2006-07-19	2010-03-17	Tabuk Pharmaceutical Manufacturing Co.	Pharmaceutical compositions of ciprofloxacin
US10363288B2 (en)	2015-01-14	2019-07-30	National Jewish Health	Insulin mimotopes and methods of using the same
US20190070299A1 (en) *	2016-02-23	2019-03-07	Matripharm International Inc.	Dual-rate release formulation with high drug loading
US9820957B2 (en)	2016-03-24	2017-11-21	The Regents Of The University Of Colorado, A Body Corporate	Methods of treating autoimmunity
US11052060B2 (en)	2018-02-12	2021-07-06	The Regents Of The University Of Colorado, A Body Corporate	Compounds and methods for treating autoimmunity
US11013707B2 (en)	2018-03-23	2021-05-25	The Regents Of The University Of Colorado, A Body Corporate	Administration of oral methyldopa
CN109806237A (zh) *	2019-03-13	2019-05-28	悦康药业集团上海制药有限公司	一种乳酸环丙沙星泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5096714A (en) *	1988-06-28	1992-03-17	Hauser-Kuhrts, Inc.	Prolonged release drug tablet formulations
JPH0624959A (ja) *	1991-10-04	1994-02-01	Bayer Yakuhin Kk	胃内浮遊型薬物徐放性固形製剤
DE4406424A1 (de) *	1994-02-28	1995-08-31	Bayer Ag	Expandierbare Arzneiformen
DE19839057A1 (de) *	1998-08-28	2000-03-02	Koch Berthold	Spülluft-Regler für eine Trockenvorrichtung für Druckluft
CA2343760A1 (en) *	1998-09-14	2000-03-23	Ranbaxy Laboratories Limited	Orally administered controlled drug delivery system providing temporal and spatial control

2001
- 2001-02-28 EA EA200200914A patent/EA200200914A1/ru unknown
- 2001-02-28 AP APAP/P/2001/002084A patent/AP2001002084A0/en unknown
- 2001-02-28 KR KR1020027011441A patent/KR20030009374A/ko not_active Ceased
- 2001-02-28 HR HRP20020715 patent/HRP20020715A2/hr not_active Application Discontinuation
- 2001-02-28 EE EEP200200497A patent/EE200200497A/xx unknown
- 2001-02-28 IL IL15155301A patent/IL151553A0/xx unknown
- 2001-02-28 BR BR0108958-7A patent/BR0108958A/pt not_active IP Right Cessation
- 2001-02-28 CA CA002400950A patent/CA2400950A1/en not_active Abandoned
- 2001-02-28 JP JP2001563081A patent/JP2003525229A/ja not_active Withdrawn
- 2001-02-28 NZ NZ520927A patent/NZ520927A/xx unknown
- 2001-02-28 AP APAP/P/2002/002627A patent/AP1485A/en active
- 2001-02-28 PL PL01365071A patent/PL365071A1/pl not_active Application Discontinuation
- 2001-02-28 SK SK1254-2002A patent/SK12542002A3/sk unknown
- 2001-02-28 YU YU66202A patent/YU66202A/sh unknown
- 2001-02-28 EP EP01908038A patent/EP1263409A1/en not_active Withdrawn
- 2001-02-28 CN CN01805998A patent/CN1420763A/zh active Pending
- 2001-02-28 AU AU35897/01A patent/AU3589701A/en not_active Abandoned
- 2001-02-28 AR ARP010100957A patent/AR032614A1/es not_active Application Discontinuation
- 2001-02-28 CZ CZ20022883A patent/CZ20022883A3/cs unknown
- 2001-02-28 HU HU0204417A patent/HUP0204417A3/hu unknown
- 2001-02-28 WO PCT/IB2001/000279 patent/WO2001064183A1/en not_active Ceased
- 2001-02-28 MX MXPA02008568A patent/MXPA02008568A/es unknown
- 2001-02-28 OA OA1200200267A patent/OA12381A/en unknown
- 2001-03-01 PE PE2001000206A patent/PE20011113A1/es not_active Application Discontinuation
- 2001-03-01 GT GT200100033A patent/GT200100033A/es unknown
- 2001-03-01 EC EC2001003952A patent/ECSP013952A/es unknown
- 2001-03-02 DO DO2001000130A patent/DOP2001000130A/es unknown
- 2001-03-02 HN HN2001000038A patent/HN2001000038A/es unknown
2002
- 2002-08-23 ZA ZA200206764A patent/ZA200206764B/en unknown
- 2002-08-28 IS IS6532A patent/IS6532A/is unknown
- 2002-08-28 NO NO20024108A patent/NO20024108L/no unknown
- 2002-09-02 BG BG107055A patent/BG107055A/bg unknown

Also Published As

Publication number	Publication date
AP1485A (en)	2005-10-31
EA200200914A1 (ru)	2003-02-27
KR20030009374A (ko)	2003-01-29
PL365071A1 (pl)	2004-12-27
CZ20022883A3 (cs)	2003-04-16
CN1420763A (zh)	2003-05-28
CA2400950A1 (en)	2001-09-07
WO2001064183A1 (en)	2001-09-07
BR0108958A (pt)	2003-09-30
ZA200206764B (en)	2003-03-04
NZ520927A (en)	2003-06-30
OA12381A (en)	2004-09-06
IS6532A (is)	2002-08-28
IL151553A0 (en)	2003-04-10
AU3589701A (en)	2001-09-12
AP2002002627A0 (en)	2002-09-30
YU66202A (sh)	2005-09-19
SK12542002A3 (sk)	2003-05-02
ECSP013952A (es)	2002-04-23
EP1263409A1 (en)	2002-12-11
JP2003525229A (ja)	2003-08-26
NO20024108D0 (no)	2002-08-28
EE200200497A (et)	2004-02-16
NO20024108L (no)	2002-10-25
AR032614A1 (es)	2003-11-19
HRP20020715A2 (en)	2004-12-31
MXPA02008568A (es)	2003-02-24
HUP0204417A3 (en)	2005-03-29
AP2001002084A0 (en)	2001-03-31
GT200100033A (es)	2001-10-25
HUP0204417A2 (en)	2003-05-28
PE20011113A1 (es)	2001-10-14
DOP2001000130A (es)	2004-03-31
HN2001000038A (es)	2005-03-23

Publication	Publication Date	Title
US6261601B1 (en)	2001-07-17	Orally administered controlled drug delivery system providing temporal and spatial control
AU758324B2 (en)	2003-03-20	Orally administered controlled drug delivery system providing temporal and spatial control
US20050276852A1 (en)	2005-12-15	Sustained release formulations of guaifenesin and additional drug ingredients
JP2013519726A (ja)	2013-05-30	バクロフェン療法に感受性の病状の治療方法
MXPA02008568A (es)	2003-02-24	Sistema de suministro controlado oralmente administrado para administracion de una vez al dia de ciprofloxacina.
EP4313014A1 (en)	2024-02-07	A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained
AU2006201553A1 (en)	2006-05-11	Orally administered controlled delivery system for once daily administration of ciprofloxacin
KR20230088399A (ko)	2023-06-19	듀테트라베나진을 포함하는 위체류성 제형
HK1053422A (en)	2003-10-24	Orally administered controlled drug delivery system providing temporal and spatial control
CN112137978A (zh)	2020-12-29	一种胃保留改性释放的固体药物组合物、制备方法及应用
HK1037967B (en)	2004-02-27	Orally administered controlled drug delivery system providing temporal and spatial control